| 초록 |
The concept of immunogenic cell death (ICD) provides the theoretical possibility to annihilate tumor and incite antigen presenting cells (APCs) to recognize it at once. Recently, it was shown that stimulator of interferon gene (STING) activation has pivotal roles in activating APCs and reprogramming TME, which is closely related to ICD. Herein, a nanocarrier co-encapsulated with ICD inducer, doxorubicin, and STING activator, diABZI STING agonist 3, is suggested. This system is able to target the cancer cells by surface modification with cyclic RGD and to be delivered in the cytosol by endo/lysosomal escape. Tumor-specific dual-activation of ICD and STING showed great improvement in tumor suppression and adaptive immunity. Furthermore, cytokines related to STING activation reprogramed the immune cells in TME. Hence, the novel strategy, that is, co-delivery of ICD inducer and STING activator into the tumor is offered as a potential pre-clinical candidate for cancer chemo-immunotherapy. |
